Preferred Label : Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination;
MeSH definition : A pharmaceutical preparation of sitagliptin phosphate and metformin hydrochloride
that is used in the treatment of TYPE 2 DIABETES.;
MeSH synonym : Sitagliptin Phosphate-Metformin Hydrochloride Drug Combination; Sitagliptin Phosphate Metformin Hydrochloride Drug Combination;
MeSH hyponym : janumet;
Wikipedia link : https://en.wikipedia.org/wiki/Janumet;
Is substance : O;
Origin ID : D000068899;
UMLS CUI : C4042818;
ATC code(s)
- Allowable qualifiers
- CISMeF manual mappings
- Record concept(s)
- Semantic type(s)
- Validated automatic mappings to BTNT
A pharmaceutical preparation of sitagliptin phosphate and metformin hydrochloride
that is used in the treatment of TYPE 2 DIABETES.
https://www.has-sante.fr/jcms/p_3283461/fr/janumet-sitagliptine-/-metformine
2021
false
false
false
France
evaluation of the transparency committee
dipeptidyl-peptidase iv inhibitors
incretins
Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
treatment outcome
insurance, health, reimbursement
metformin and sitagliptin
diabetes mellitus, type 2
hypoglycemic agents
adult
---
https://www.has-sante.fr/jcms/p_3284305/fr/velmetia-sitagliptine-/-metformine
2021
false
false
false
France
evaluation of the transparency committee
drug combinations
administration, oral
treatment outcome
hypoglycemic agents
diabetes mellitus, type 2
Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
metformin and sitagliptin
---
https://rmlg.uliege.be/article/2456
2013
false
false
false
Belgium
French
journal article
sitagliptin
diabetes mellitus, type 2
treatment outcome
hypoglycemic agents
dipeptidyl-peptidase iv inhibitors
administration, oral
metformin and sitagliptin
renal insufficiency
incretins
clinical trials as topic
dipeptidyl-peptidase iv inhibitors
incretins
hypoglycemic agents
Drug-induced acute pancreatitis (disorder)
pancreatic neoplasms
pancreatitis
belgium
insurance, health, reimbursement
cardiovascular diseases
Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
Sitagliptin Phosphate
Sitagliptin Phosphate
---
https://www.ema.europa.eu/medicines/human/EPAR/Janumet
2012
false
United Kingdom
English
French
syndication feed
Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
dipeptidyl-peptidase iv inhibitors
drug therapy, combination
drug combinations
hypoglycemic agents
hypoglycemic agents
dipeptidyl-peptidase iv inhibitors
tablets
administration, oral
diabetes mellitus, type 2
drug approval
treatment outcome
drug labeling
aged
adult
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
metformin and sitagliptin
drug evaluation
summary of product characteristics
package leaflet
---
https://www.ema.europa.eu/medicines/human/EPAR/Efficib
2012
false
United Kingdom
French
English
syndication feed
Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
dipeptidyl-peptidase iv inhibitors
drug therapy, combination
drug combinations
dipeptidyl-peptidase iv inhibitors
hypoglycemic agents
hypoglycemic agents
diabetes mellitus, type 2
tablets
administration, oral
adult
aged
drug approval
treatment outcome
drug labeling
drug interactions
breast feeding
pregnancy
drug evaluation, preclinical
metformin and sitagliptin
drug evaluation
summary of product characteristics
package leaflet
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-08/xelevia_velmetia_18072012_avis_ct8855_ct8856.pdf
http://www.has-sante.fr/portail/jcms/c_1284610/xelevia-velmetia
2012
false
France
French
evaluation of the transparency committee
Sitagliptin Phosphate
Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
administration, oral
insurance, health, reimbursement
metformin and sitagliptin
sitagliptin
dipeptidyl-peptidase iv inhibitors
hypoglycemic agents
diabetes mellitus, type 2
drug combinations
drug therapy, combination
insulin
adult
aged
---
http://www.has-sante.fr/portail/jcms/c_1340115/januvia-et-xelevia-sitagliptine-inhibiteur-de-la-dpp-4-janumet-et-velmetia-sitagliptine/metformine
http://www.has-sante.fr/portail/jcms/c_1340114/januvia-janumet-xelevia-velmetia-18072012-synthese
http://www.has-sante.fr/portail/jcms/c_1284968/januvia-janumet-18072012-avis-ct9807-ct9808-ct11768-ct11968
http://www.has-sante.fr/portail/jcms/c_1284991/xelevia-velmetia-18072012-avis-ct8855-ct8856
2012
false
France
French
Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
Sitagliptin Phosphate
administration, oral
drug therapy, combination
insulin
metformin and sitagliptin
sitagliptin
drug combinations
dipeptidyl-peptidase iv inhibitors
diabetes mellitus, type 2
insurance, health, reimbursement
treatment outcome
Glycated Hemoglobin
evaluation of the transparency committee
guidelines for drug use
---
https://www.ema.europa.eu/medicines/human/EPAR/Ristfor
2012
false
United Kingdom
English
French
syndication feed
Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
metformin and sitagliptin
drug interactions
adult
aged
pregnancy
breast feeding
drug evaluation, preclinical
drug combinations
drug approval
drug labeling
treatment outcome
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
hypoglycemic agents
hypoglycemic agents
administration, oral
diabetes mellitus, type 2
drug therapy, combination
drug evaluation
summary of product characteristics
package leaflet
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2012-08/januvia_janumet_18072012_avis_ct9807_ct9808_ct11768_ct11968.pdf
http://www.has-sante.fr/portail/jcms/c_1284613/januvia-janumet
2012
false
France
French
evaluation of the transparency committee
Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
Sitagliptin Phosphate
drug combinations
administration, oral
dipeptidyl-peptidase iv inhibitors
hypoglycemic agents
metformin and sitagliptin
sitagliptin
diabetes mellitus, type 2
insurance, health, reimbursement
drug therapy, combination
insulin
adult
aged
treatment outcome
clinical trials, phase iii as topic
---
https://www.ema.europa.eu/medicines/human/EPAR/Velmetia
2012
false
United Kingdom
English
French
syndication feed
Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
drug combinations
administration, oral
drug approval
treatment outcome
drug labeling
diabetes mellitus, type 2
hypoglycemic agents
hypoglycemic agents
drug therapy, combination
dipeptidyl-peptidase iv inhibitors
dipeptidyl-peptidase iv inhibitors
adult
aged
drug interactions
breast feeding
pregnancy
drug evaluation, preclinical
metformin and sitagliptin
drug evaluation
summary of product characteristics
package leaflet
---
http://www.has-sante.fr/portail/jcms/c_799834/janumet-ct-6403
http://www.has-sante.fr/portail/jcms/c_799107/velmetia-ct-6479
http://www.has-sante.fr/portail/jcms/c_841944/janumet-et-velmetia-sitagliptine-/-metformine-antidiabetique-oral
2009
false
France
French
Sitagliptin Phosphate, Metformin Hydrochloride Drug Combination
diabetes mellitus, type 2
hypoglycemic agents
drug combinations
administration, oral
dipeptidyl-peptidase iv inhibitors
treatment outcome
metformin and sitagliptin
guidelines for drug use
evaluation of the transparency committee
---
